Trust your gut when it comes to driving CARs
- PMID: 35584646
- DOI: 10.1016/j.medj.2022.04.015
Trust your gut when it comes to driving CARs
Abstract
Chimeric Antigen Receptor (CAR) T-cells have revolutionized the treatment of hematologic malignancies, but limitations exist in poor predictability and in observable toxicity with response to treatment. Here, Smith et al. present the gut microbiome as an actionable (and potentially targetable) biomarker of response and toxicity with (CD19) CAR T-cell treatment.1.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests J.A.W. is an inventor on a US patent application (PCT/US17/53.717); reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, MedImmune, and Bristol-Myers Squibb (BMS); serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline (GSK), BMS, Merck, Biothera Pharmaceuticals, and Micronoma. J.A.W. holds stock options from Micronoma.
Comment on
-
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy.Nat Med. 2022 Apr;28(4):713-723. doi: 10.1038/s41591-022-01702-9. Epub 2022 Mar 14. Nat Med. 2022. PMID: 35288695 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources